HIV

HIV is the human immunodeficiency virus, a retrovirus that attacks the body’s immune system by targeting CD4+ T cells, progressively weakening the body’s ability to fight infections and certain cancers. HIV is transmitted through contact with infected blood, semen, vaginal fluids, rectal fluids, and breast milk, primarily through unprotected sexual contact, sharing injection equipment, and from mother to child during pregnancy, birth, or breastfeeding. At the global level, HIV affects approximately 39 million people worldwide, making it one of the most significant public health challenges of the modern era.

Since the beginning of the epidemic, over 88 million people have been infected with HIV and about 42 million people have died from AIDS-related causes. The annual number of new HIV infections has declined by 39% since its peak in 1995, while AIDS-related deaths have fallen by 69% since their peak in 2004, largely due to the scale-up of antiretroviral therapy and prevention programs.

Without treatment, HIV typically progresses to AIDS (acquired immunodeficiency syndrome) within 8-10 years, characterized by severe immunodeficiency and opportunistic infections. Comprehensive HIV awareness encompasses knowledge of prevention methods, testing, treatment options, and strategies for living a healthy life with HIV while preventing transmission to others.

History

Pre-1980: Origins and Early Spread

HIV is believed to have crossed from non-human primates to humans in central Africa in the early 20th century, with genetic analysis suggesting the pandemic strain (HIV-1 Group M) emerged around 1908 in present-day Democratic Republic of Congo. The virus likely spread gradually through trade routes and urbanization before accelerating globally in the mid-20th century.

1981: First Clinical Recognition

The CDC published the first report of what would later be recognized as AIDS on June 5, 1981, describing five cases of Pneumocystis carinii pneumonia in previously healthy gay men in Los Angeles. This date is now observed as the beginning of the HIV/AIDS pandemic recognition.

1982: AIDS Definition and Naming

The CDC established the first case definition for AIDS and officially named the syndrome “acquired immunodeficiency syndrome.” Early names included GRID (gay-related immune deficiency), but AIDS was adopted to reflect the disease’s broader impact beyond gay communities.

1983-1984: Viral Discovery

French researchers at the Pasteur Institute, led by Luc Montagnier and Françoise Barré-Sinoussi, first isolated the virus causing AIDS, initially called LAV (lymphadenopathy-associated virus). American researcher Robert Gallo simultaneously identified HTLV-III, later confirmed to be the same virus, eventually named HIV.

1985: First HIV Test and International Response

The first commercial HIV antibody test was approved, revolutionizing diagnosis and blood screening. Rock Hudson became the first major celebrity to die from AIDS, bringing unprecedented public attention to the epidemic and reducing stigma through increased awareness.

1987: First HIV Treatment

AZT (zidovudine) became the first antiretroviral drug approved for HIV treatment, though early monotherapy provided limited benefit and significant toxicity. ACT UP (AIDS Coalition to Unleash Power) was founded, becoming a powerful advocacy organization for treatment access and research acceleration.

1990s: Treatment Revolution

The development of protease inhibitors and combination therapy (HAART – highly active antiretroviral therapy) in the mid-1990s transformed HIV from a fatal diagnosis to a manageable chronic condition in resource-rich settings. Deaths began declining dramatically in countries with treatment access.

2000s: Global Treatment Scale-Up

The establishment of PEPFAR (President’s Emergency Plan for AIDS Relief) in 2003 and the Global Fund to Fight AIDS, Tuberculosis and Malaria led to massive increases in treatment access worldwide, saving millions of lives in low- and middle-income countries.

2010s-Present: Prevention and Cure Research

Pre-exposure prophylaxis (PrEP) was approved in 2012, providing highly effective HIV prevention for high-risk individuals. Treatment as prevention (U=U: undetectable = untransmittable) became widely accepted, and cure research intensified with several cases of HIV remission following stem cell transplants.

Viral Biology and Pathogenesis

Virus Structure and Classification

HIV is a lentivirus belonging to the retrovirus family, characterized by its ability to integrate its genetic material into the host cell’s DNA. HIV exists as two main types: HIV-1 (responsible for the global pandemic) and HIV-2 (primarily found in West Africa), with HIV-1 further divided into groups and subtypes with different geographic distributions.

Life Cycle and Replication

HIV primarily targets CD4+ T cells, macrophages, and dendritic cells by binding to the CD4 receptor and co-receptors (CCR5 or CXCR4). After entry, the virus uses reverse transcriptase to convert its RNA genome into DNA, which integrates into the host cell’s chromosome, establishing a persistent reservoir that current treatments cannot eliminate.

Immune System Progression

HIV infection progresses through three stages: acute infection (2-4 weeks post-infection with high viral loads), chronic infection (gradual CD4+ cell decline over years), and AIDS (CD4+ count below 200 cells/μL or presence of defining opportunistic infections). Without treatment, median survival is 9-11 years from infection.

Viral Reservoirs and Latency

HIV establishes latent reservoirs in resting CD4+ T cells and other anatomical sites, making complete viral elimination extremely challenging. These reservoirs are the primary barrier to HIV cure, as they can reactivate viral production even during effective antiretroviral therapy.

Global HIV Patterns

Regional Epidemics

Sub-Saharan Africa bears the greatest burden with 25.6 million people living with HIV (67% of global cases), while Eastern Europe and Central Asia show the fastest-growing epidemics. The Caribbean has the second-highest adult prevalence (1.1%), followed by Southern Africa where some countries have adult prevalence rates exceeding 20%.

Key Populations

Globally, key populations (sex workers, men who have sex with men, people who inject drugs, transgender people, and prisoners) account for 70% of new HIV infections despite representing a small fraction of the total population. These groups face disproportionate risks due to biological, behavioral, and structural factors.

Gender and Age Patterns

Women comprise 53% of people living with HIV globally, with particularly high rates among young women aged 15-24 in sub-Saharan Africa. Adolescent girls and young women in this region are three times more likely to acquire HIV than their male peers due to biological, social, and economic vulnerabilities.

Mother-to-Child Transmission

Without intervention, HIV transmission rates from mother to child range from 15-30%, but can be reduced to less than 2% with effective antiretroviral treatment, safe delivery practices, and appropriate infant feeding strategies. Several countries have achieved elimination of mother-to-child transmission.

Transmission and Prevention

Routes of Transmission

HIV is transmitted through sexual contact (accounting for over 95% of new adult infections globally), sharing injection equipment, mother-to-child transmission, and rarely through blood transfusions or occupational exposure. The virus is not transmitted through casual contact, air, water, or insect bites.

Sexual Transmission Risk Factors

Anal intercourse carries the highest per-act transmission risk (1.4% receptive, 0.11% insertive), followed by vaginal intercourse (0.08% female-to-male, 0.04% male-to-female). Risk factors include high viral load, concurrent STIs, lack of male circumcision, and mucosal trauma during sexual activity.

Prevention Methods

Effective prevention strategies include consistent condom use (80-95% risk reduction), pre-exposure prophylaxis (PrEP) for high-risk individuals (90%+ effectiveness), male circumcision (60% risk reduction for heterosexual men), and treatment as prevention (near-zero transmission risk when virally suppressed). Combination prevention approaches are most effective when tailored to specific populations and epidemiological contexts.

Injection Drug Use Prevention

Harm reduction strategies including needle and syringe programs, opioid substitution therapy, and drug treatment services can reduce HIV transmission among people who inject drugs by 50% or more. These interventions are cost-effective and have been endorsed by major international health organizations.

Testing and Diagnosis

Testing Technologies

HIV testing has evolved from early antibody tests requiring laboratory processing to rapid point-of-care tests providing results in 15-20 minutes. Fourth-generation tests can detect both antibodies and viral antigen, reducing the window period to 2-4 weeks after infection.

Testing Strategies

WHO recommends the “3 test strategy” for HIV diagnosis in resource-limited settings, using sequential rapid tests with different antigens to confirm positive results. Self-testing has emerged as an important strategy to reach populations who may not access traditional testing services.

Window Period and Acute Infection

The window period between infection and detectable antibodies varies by test type, from 10-33 days for laboratory-based tests to 18-90 days for rapid tests. During acute infection, HIV RNA or antigen tests may be needed for diagnosis, as this period is associated with very high viral loads and transmission risk.

Treatment and Care

Antiretroviral Therapy (ART)

Modern ART typically consists of three drugs from at least two different classes, including nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), and entry/fusion inhibitors. Current regimens are highly effective, well-tolerated, and often require only one pill daily.

Treatment Guidelines and Goals

Current guidelines recommend immediate ART initiation for all people diagnosed with HIV, regardless of CD4+ count, based on evidence showing better outcomes with early treatment. The goal is achieving and maintaining viral suppression (undetectable viral load), which preserves immune function and prevents transmission.

Drug Resistance

HIV drug resistance can develop due to incomplete viral suppression, medication adherence issues, or transmission of resistant strains. Resistance testing is recommended before starting treatment and after treatment failure to guide optimal regimen selection. Pre-treatment drug resistance is increasing globally, particularly to NNRTIs.

Long-Acting Therapies

Injectable long-acting antiretroviral formulations administered monthly or every two months have been approved, offering alternatives for people who prefer less frequent dosing. These formulations may improve adherence and quality of life for some patients.

Opportunistic Infections and Comorbidities

AIDS-Defining Conditions

AIDS is diagnosed when CD4+ counts fall below 200 cells/μL or when certain opportunistic infections occur, including Pneumocystis pneumonia, tuberculosis, toxoplasmosis, cryptococcal meningitis, and Kaposi’s sarcoma. These conditions rarely occur in people with access to effective ART.

Non-AIDS Comorbidities

People with HIV have increased rates of cardiovascular disease, certain cancers, bone disease, kidney disease, and neurocognitive disorders, even when virally suppressed. These conditions are influenced by chronic inflammation, immune activation, drug toxicities, and traditional risk factors.

HIV and Tuberculosis Co-infection

Tuberculosis is the leading cause of death among people with HIV, with HIV increasing TB risk by 20-40 fold. Co-infection complicates treatment of both diseases and requires careful coordination of therapies to avoid drug interactions and immune reconstitution inflammatory syndrome (IRIS).

Social and Economic Impact

Stigma and Discrimination

HIV-related stigma remains a major barrier to testing, treatment, and prevention services worldwide. Stigma manifests in healthcare settings, employment, housing, and relationships, contributing to poor health outcomes and mental health problems among people with HIV.

Economic Burden

HIV treatment costs approximately $20,000-35,000 annually per person in high-income countries, while generic formulations in low-income settings cost $100-300 annually. The lifetime economic burden of HIV infection is estimated at $300,000-500,000 per person in the United States.

Human Rights and Criminalization

Many countries criminalize HIV transmission or non-disclosure, often based on outdated science and contributing to stigma. Human rights approaches emphasizing dignity, equality, and evidence-based policies are more effective at reducing HIV transmission and improving health outcomes.

Prevention Science and PrEP

Pre-Exposure Prophylaxis

Daily oral PrEP (tenofovir/emtricitabine) reduces HIV risk by over 90% when taken consistently, making it one of the most effective biomedical prevention tools available. Long-acting injectable PrEP (cabotegravir) administered every two months shows superior efficacy in clinical trials.

Treatment as Prevention

People with HIV who achieve and maintain viral suppression through ART do not transmit HIV sexually (U=U: undetectable equals untransmittable). This concept has revolutionized prevention messaging and reduced HIV-related stigma while emphasizing the importance of treatment adherence.

Microbicides and Vaccines

Topical microbicides have shown modest efficacy in some studies, while HIV vaccine research continues despite decades of challenges. Recent advances in broadly neutralizing antibodies and novel vaccine platforms offer renewed hope for effective HIV prevention vaccines.

Cure Research

Types of Cure Strategies

HIV cure research focuses on two main approaches: sterilizing cure (complete viral elimination) and functional cure (long-term viral control without ART). Several cases of HIV remission have been achieved through stem cell transplantation, but these procedures are too risky for widespread use.

Shock and Kill Strategies

Latency reversal agents aim to reactivate dormant HIV reservoirs, making infected cells vulnerable to immune clearance or direct killing. However, early trials have shown limited success, highlighting the complexity of achieving HIV cure.

Block and Lock Approaches

Alternative strategies focus on permanently silencing HIV reservoirs rather than eliminating them, potentially achieving functional cure with less toxicity than elimination approaches. Research continues on epigenetic modifications and other mechanisms to maintain viral suppression.

Future Directions and Global Goals

UNAIDS 95-95-95 Targets

The global goal aims for 95% of people with HIV to know their status, 95% of diagnosed people to receive treatment, and 95% of treated people to achieve viral suppression by 2030. Achieving these targets could effectively end the AIDS pandemic as a public health threat.

Emerging Technologies

Long-acting formulations, broadly neutralizing antibodies, genetic approaches including gene editing, and novel delivery systems represent the next generation of HIV prevention and treatment tools. Cutting-edge HIV research continues to advance toward more effective, convenient, and accessible interventions.

Health System Strengthening

Sustainable HIV responses require robust health systems, community engagement, and addressing structural factors including poverty, gender inequality, and human rights violations that drive HIV vulnerability and limit access to services.

Frequently Asked Questions

How is HIV transmitted?
HIV spreads through contact with infected blood, semen, vaginal fluids, rectal fluids, and breast milk. The most common routes are unprotected sexual contact and sharing injection equipment. HIV is not transmitted through casual contact, saliva, sweat, or insect bites.

How long can someone live with HIV?
With early diagnosis and effective treatment, people with HIV can live normal lifespans. Studies show that people diagnosed with HIV in their 20s and starting treatment promptly can expect to live into their 70s, similar to HIV-negative individuals.

When should I get tested for HIV?
CDC recommends at least one HIV test for everyone aged 13-64 as part of routine healthcare, and annual testing for people at higher risk. Get tested immediately after potential exposure and again at 3 months, as most tests have a window period before infection can be detected.

What is PrEP and who should take it?
Pre-exposure prophylaxis (PrEP) is a daily medication that prevents HIV infection in people at high risk. It’s recommended for people with HIV-positive partners, multiple partners, injection drug users, and others at substantial risk. PrEP is over 90% effective when taken consistently.

Can people with HIV have children safely?
Yes, with proper medical care, people with HIV can have children with very low risk of transmission. Treatment during pregnancy reduces mother-to-child transmission risk to less than 2%, and HIV-positive partners can conceive safely using treatment as prevention or PrEP.

What does “undetectable equals untransmittable” mean?
When HIV treatment reduces viral load to undetectable levels (less than 50 copies/mL), there is no risk of sexual transmission to partners. This concept, known as U=U, is supported by large studies showing zero transmissions from virally suppressed partners.

Is there a cure for HIV?
Currently, there is no widely available cure for HIV, though several individuals have achieved HIV remission through complex medical procedures. However, modern HIV treatment is highly effective at controlling the virus and preventing progression to AIDS, allowing people with HIV to live healthy, normal lives.

Related Entries

• Genital herpes
• Urethritis
• Birth control
• Pap smear
• 0-day pregnancy test